Imaging Biometrics of Elm Grove, WI, is touting preliminary results from a study that it says has validated a perfusion MRI (pMRI) technology with stereotactic tissue biopsy results.
The proprietary technology contained in the company's IB Neuro software had an accuracy of 96% when distinguishing tumor from post-treatment radiation effects, according to a study led by cancer researchers at Imaging Biometrics and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center (BNI-SJHMC) in Phoenix.
IB Neuro uses dynamic susceptibility contrast perfusion algorithms to provide information about blood volume and blood flow in the brain. The perfusion parameters are designed to detect the growth of new tumor blood vessels. The information allows clinicians to more accurately diagnose tumor aggressiveness and potentially predict responses to antitumor therapies.
Researchers at BNI-SJHMC are developing a method to correlate imaging measurements with biopsied tumor samples, which have shown promise in validating techniques using IB Neuro.
Related Reading
Imaging Biometrics inks deal with Clario, June 3, 2009
Imaging Biometrics to contribute to ACRIN, June 12, 2008
FDA clears MR perfusion package, June 6, 2008
Copyright © 2009 AuntMinnie.com
